20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
The CEO of Novo Nordisk (NYSE:NVO), Lars Fruergaard Jorgensen, announced on Friday that the company plans to collaborate with European healthcare systems. The aim is to improve access to its weight-loss drug, Wegovy, for less fortunate and more obese individuals, according to Reuters.
“We can see that the demand for the medicine is so strong, that we actually have to be more intentional in how we actually get through to the patients we would like to get through to and how we collaborate with healthcare systems,” Jorgensen said.
Jorgensen stated at a Reuters Newsmaker event, “In Europe, we would aim to seek reimbursement for those patients with the highest BMI, have co-morbidities, and perhaps also those less fortunate from a socio-economic point of view.”
The Denmark-based company’s injectable Wegovy is a leading product in a new class of highly effective weight-loss drugs. When used alongside dietary and exercise changes, Wegovy leads to an average weight loss of around 15%. Another injectable drug from Novo Nordisk, Ozempic, is becoming a popular choice among celebrities as a ‘miracle’ weightloss drug.
Read Next: These Three New Markets May Propel Novo Nordisk’s Ozempic To Greater Heights
Image Via Shutterstock
Engineered by Benzinga Neuro, Edited by Pooja Rajkumari
The GPT-4 Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. Learn more.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!